TRIS PHARMA INC Company Profile
✉ Email this page to a colleague
What is the competitive landscape for TRIS PHARMA INC, and what generic alternatives to TRIS PHARMA INC drugs are available?
TRIS PHARMA INC has thirty approved drugs.
There are twelve US patents protecting TRIS PHARMA INC drugs.
There are nineteen patent family members on TRIS PHARMA INC drugs in fourteen countries and twenty-eight supplementary protection certificates in ten countries.
Summary for TRIS PHARMA INC
| International Patents: | 19 |
| US Patents: | 12 |
| Tradenames: | 30 |
| Ingredients: | 25 |
| NDAs: | 30 |
| Drug Master File Entries: | 6 |
Drugs and US Patents for TRIS PHARMA INC
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tris Pharma Inc | RISPERIDONE | risperidone | SOLUTION;ORAL | 079059-001 | Dec 12, 2012 | AA | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ||||
| Tris Pharma Inc | DYANAVEL XR 5 | amphetamine; amphetamine aspartate/dextroamphetamine sulfate | TABLET, EXTENDED RELEASE;ORAL | 210526-001 | Nov 4, 2021 | RX | Yes | No | 11,590,081 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Tris Pharma Inc | DYANAVEL XR 10 | amphetamine; amphetamine aspartate/dextroamphetamine sulfate | TABLET, EXTENDED RELEASE;ORAL | 210526-002 | Nov 4, 2021 | RX | Yes | No | 8,337,890 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Tris Pharma Inc | DYANAVEL XR 15 | amphetamine; amphetamine aspartate/dextroamphetamine sulfate | TABLET, EXTENDED RELEASE;ORAL | 210526-003 | Nov 4, 2021 | RX | Yes | No | 9,675,704 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for TRIS PHARMA INC Drugs
Supplementary Protection Certificates for TRIS PHARMA INC Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1718641 | SPC/GB12/028 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: AZILSARTAN MEDOXOMIL AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, INCLUDING THE POTASSIUM SALT; REGISTERED: UK EU/1/11/734/001-011 20111209 |
| 1781277 | PA2024501 | Lithuania | ⤷ Sign Up | PRODUCT NAME: IBUPROFENO IR PARACETAMOLIO DERINYS; REGISTRATION NO/DATE: LT/1/23/5212/001-002 20230726 |
| 1441735 | SPC/GB08/020 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: RALTEGRAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, ESPECIALLY THE POTASSIUM SALT; REGISTERED: UK EU/1/07/436/001 20080102 |
| 0733366 | SPC/GB98/031 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: 2-BUTYL-4-CHLORO-1-((2'-(1H-TETRAZOL-5-YL) BIPHENYL-4-YL)-METHYL)-5-(HYDROXYMETHYL)IMIDAZOLE (LOSARTAN),OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, IN PARTICULAR A POTASSIUM SALT( LOSARTAN POTASSIUM) AND HYDROCHLOROTHIAZIDE,; REGISTERED: FR 338520.7 19950215; FR 558453.7 19950215; UK 00025/0338 19960412 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
